{
    "id": 27021,
    "fullName": "CD79B Y196D",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "CD79B Y196D lies within the ITAM domain of the Cd79b protein (UniProt.org). Y196D results in increased phosphorylation of S6RP and 4EBP1 in culture and demonstrates sensitivity to PI3K inhibitors in vivo and therefore, is predicted to result in a gain of Cd79b protein function (PMID: 28619981).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 10035,
                    "pubMedId": 28619981,
                    "title": "Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619981"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 974,
        "geneSymbol": "CD79B",
        "terms": [
            "CD79B",
            "AGM6",
            "B29",
            "IGB"
        ]
    },
    "variant": "Y196D",
    "createDate": "10/03/2017",
    "updateDate": "10/03/2017",
    "referenceTranscriptCoordinates": {
        "id": 108773,
        "transcript": "NM_000626",
        "gDna": "chr17:g.63929439A>C",
        "cDna": "c.586T>G",
        "protein": "p.Y196D",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12108,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with primary central nervous system lymphoma harboring CD79B Y196D, MYD88 L265P, and TNFAIP3 L324Qfs*7 demonstrated a partial response when treated with Imbruvica (ibrutinib) (PMID: 28619981).",
            "molecularProfile": {
                "id": 28412,
                "profileName": "CD79B Y196D MYD88 L265P TNFAIP3 L324Qfs*7"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3234,
                "name": "central nervous system lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10035,
                    "pubMedId": 28619981,
                    "title": "Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619981"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12109,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with primary central nervous system lymphoma harboring CD79B Y196D, MYD88 L265P, and TNFAIP3 del demonstrated a partial response when treated with Imbruvica (ibrutinib) (PMID: 28619981).",
            "molecularProfile": {
                "id": 28414,
                "profileName": "CD79B Y196D MYD88 L265P TNFAIP3 del"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3234,
                "name": "central nervous system lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10035,
                    "pubMedId": 28619981,
                    "title": "Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619981"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28399,
            "profileName": "CD79B Y196D",
            "profileTreatmentApproaches": [
                {
                    "id": 16334,
                    "name": "PKC Inhibitor (Pan)",
                    "profileName": "CD79B Y196D"
                }
            ]
        },
        {
            "id": 28412,
            "profileName": "CD79B Y196D MYD88 L265P TNFAIP3 L324Qfs*7",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28414,
            "profileName": "CD79B Y196D MYD88 L265P TNFAIP3 del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 108773,
            "transcript": "NM_000626",
            "gDna": "chr17:g.63929439A>C",
            "cDna": "c.586T>G",
            "protein": "p.Y196D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}